- Home
- IHS vs COLL Comparison
IHS vs COLL Comparison
Compare IHS & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IHS
- COLL
- Stock Information
- Founded
- IHS 2001
- COLL 2002
- Country
- IHS United Kingdom
- COLL United States
- Employees
- IHS N/A
- COLL N/A
- Industry
- IHS Telecommunications Equipment
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- IHS Telecommunications
- COLL Health Care
- Exchange
- IHS Nasdaq
- COLL Nasdaq
- Market Cap
- IHS 1.1B
- COLL 910.2M
- IPO Year
- IHS 2021
- COLL 2015
- Fundamental
- Price
- IHS $4.94
- COLL $27.01
- Analyst Decision
- IHS Strong Buy
- COLL Strong Buy
- Analyst Count
- IHS 5
- COLL 5
- Target Price
- IHS $7.60
- COLL $43.60
- AVG Volume (30 Days)
- IHS 722.6K
- COLL 500.0K
- Earning Date
- IHS 05-13-2025
- COLL 05-08-2025
- Dividend Yield
- IHS N/A
- COLL N/A
- EPS Growth
- IHS N/A
- COLL 43.56
- EPS
- IHS N/A
- COLL 1.86
- Revenue
- IHS $1,711,225,000.00
- COLL $631,449,000.00
- Revenue This Year
- IHS $0.40
- COLL $19.96
- Revenue Next Year
- IHS $5.94
- COLL $3.93
- P/E Ratio
- IHS N/A
- COLL $14.55
- Revenue Growth
- IHS N/A
- COLL 11.41
- 52 Week Low
- IHS $2.44
- COLL $23.23
- 52 Week High
- IHS $5.75
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- IHS 57.15
- COLL 43.16
- Support Level
- IHS $4.21
- COLL $23.23
- Resistance Level
- IHS $4.69
- COLL $27.57
- Average True Range (ATR)
- IHS 0.27
- COLL 1.45
- MACD
- IHS -0.03
- COLL -0.08
- Stochastic Oscillator
- IHS 66.10
- COLL 51.82
About IHS IHS Holding Limited
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, most of who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria, Sub-Saharan Africa, Middle East and North Africa (MENA), and Latin America (Latam). The majority of its revenue is derived from Nigeria.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.